Dendritic cells/natural killer cross-talk

A novel target for human immunodeficiency virus type-1 protease inhibitors

Maria Letizia Giardino Torchia, Elena Ciaglia, Anna Maria Masci, Laura Vitiello, Manuela Fogli, Andrea la Sala, Domenico Mavilio, Luigi Racioppi

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: HIV-1 Protease Inhibitors, namely PIs, originally designed to inhibit HIV-1 aspartic protease, can modulate the immune response by mechanisms largely unknown, and independent from their activity on viral replication. Here, we analyzed the ability of PIs to interfere with differentiation program of monocytes toward dendritic cell (DCs) lineage, a key process in the inflammatory response. Methodology/Principal Findings: Monocytes from healthy donors were isolated and induced to differentiate in vitro in the presence or absence of saquinavir, ritonavir, nelfinavir, indinavir or amprenavir (sqv, rtv, nlfv, idv, apv, respectively). These drugs demonstrated a differential ability to sustain the generation of immature DCs (iDCs) with an altered phenotype, including low levels of CD1a, CD86, CD36 and CD209. DCs generated in the presence of rtv also failed to acquire the typical phenotype of mature DCs (mDCs), and secreted lower amounts of IL-12 and IL-15. Accordingly, these aberrant mDCs failed to support activation of autologous Natural Killer (NK) cells, and resulted highly susceptible to NK cell-mediated cytotoxicity. Conclusions/Significance: Our findings uncover novel functional properties of PIs within the DC-NK cell cross-talk, unveiling the heterogeneous ability of members of this class drugs to drive the generation of atypical monocyte-derived DCs (MDDCs) showing an aberrant phenotype, a failure to respond appropriately to bacterial endotoxin, a weak ability to prime autologous NK cells, and a high susceptibility to NK cell killing. These unexpected properties might contribute to limit inflammation and viral spreading in HIV-1 infected patients under PIs treatment, and open novel therapeutical perspectives for this class drugs as immunomodulators in autoimmunity and cancer.

Original languageEnglish
Article numbere11052
JournalPLoS One
Volume5
Issue number6
DOIs
Publication statusPublished - 2010

Fingerprint

dendritic cells
Human immunodeficiency virus 1
proteinase inhibitors
Protease Inhibitors
Viruses
Dendritic Cells
natural killer cells
HIV-1
Natural Killer Cells
monocytes
Monocytes
Phenotype
phenotype
drugs
inflammation
Nelfinavir
Pharmaceutical Preparations
Saquinavir
Indinavir
HIV Protease Inhibitors

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Dendritic cells/natural killer cross-talk : A novel target for human immunodeficiency virus type-1 protease inhibitors. / Torchia, Maria Letizia Giardino; Ciaglia, Elena; Masci, Anna Maria; Vitiello, Laura; Fogli, Manuela; la Sala, Andrea; Mavilio, Domenico; Racioppi, Luigi.

In: PLoS One, Vol. 5, No. 6, e11052, 2010.

Research output: Contribution to journalArticle

Torchia, Maria Letizia Giardino ; Ciaglia, Elena ; Masci, Anna Maria ; Vitiello, Laura ; Fogli, Manuela ; la Sala, Andrea ; Mavilio, Domenico ; Racioppi, Luigi. / Dendritic cells/natural killer cross-talk : A novel target for human immunodeficiency virus type-1 protease inhibitors. In: PLoS One. 2010 ; Vol. 5, No. 6.
@article{7e7aee251fe94137812273683003bdac,
title = "Dendritic cells/natural killer cross-talk: A novel target for human immunodeficiency virus type-1 protease inhibitors",
abstract = "Background: HIV-1 Protease Inhibitors, namely PIs, originally designed to inhibit HIV-1 aspartic protease, can modulate the immune response by mechanisms largely unknown, and independent from their activity on viral replication. Here, we analyzed the ability of PIs to interfere with differentiation program of monocytes toward dendritic cell (DCs) lineage, a key process in the inflammatory response. Methodology/Principal Findings: Monocytes from healthy donors were isolated and induced to differentiate in vitro in the presence or absence of saquinavir, ritonavir, nelfinavir, indinavir or amprenavir (sqv, rtv, nlfv, idv, apv, respectively). These drugs demonstrated a differential ability to sustain the generation of immature DCs (iDCs) with an altered phenotype, including low levels of CD1a, CD86, CD36 and CD209. DCs generated in the presence of rtv also failed to acquire the typical phenotype of mature DCs (mDCs), and secreted lower amounts of IL-12 and IL-15. Accordingly, these aberrant mDCs failed to support activation of autologous Natural Killer (NK) cells, and resulted highly susceptible to NK cell-mediated cytotoxicity. Conclusions/Significance: Our findings uncover novel functional properties of PIs within the DC-NK cell cross-talk, unveiling the heterogeneous ability of members of this class drugs to drive the generation of atypical monocyte-derived DCs (MDDCs) showing an aberrant phenotype, a failure to respond appropriately to bacterial endotoxin, a weak ability to prime autologous NK cells, and a high susceptibility to NK cell killing. These unexpected properties might contribute to limit inflammation and viral spreading in HIV-1 infected patients under PIs treatment, and open novel therapeutical perspectives for this class drugs as immunomodulators in autoimmunity and cancer.",
author = "Torchia, {Maria Letizia Giardino} and Elena Ciaglia and Masci, {Anna Maria} and Laura Vitiello and Manuela Fogli and {la Sala}, Andrea and Domenico Mavilio and Luigi Racioppi",
year = "2010",
doi = "10.1371/journal.pone.0011052",
language = "English",
volume = "5",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "6",

}

TY - JOUR

T1 - Dendritic cells/natural killer cross-talk

T2 - A novel target for human immunodeficiency virus type-1 protease inhibitors

AU - Torchia, Maria Letizia Giardino

AU - Ciaglia, Elena

AU - Masci, Anna Maria

AU - Vitiello, Laura

AU - Fogli, Manuela

AU - la Sala, Andrea

AU - Mavilio, Domenico

AU - Racioppi, Luigi

PY - 2010

Y1 - 2010

N2 - Background: HIV-1 Protease Inhibitors, namely PIs, originally designed to inhibit HIV-1 aspartic protease, can modulate the immune response by mechanisms largely unknown, and independent from their activity on viral replication. Here, we analyzed the ability of PIs to interfere with differentiation program of monocytes toward dendritic cell (DCs) lineage, a key process in the inflammatory response. Methodology/Principal Findings: Monocytes from healthy donors were isolated and induced to differentiate in vitro in the presence or absence of saquinavir, ritonavir, nelfinavir, indinavir or amprenavir (sqv, rtv, nlfv, idv, apv, respectively). These drugs demonstrated a differential ability to sustain the generation of immature DCs (iDCs) with an altered phenotype, including low levels of CD1a, CD86, CD36 and CD209. DCs generated in the presence of rtv also failed to acquire the typical phenotype of mature DCs (mDCs), and secreted lower amounts of IL-12 and IL-15. Accordingly, these aberrant mDCs failed to support activation of autologous Natural Killer (NK) cells, and resulted highly susceptible to NK cell-mediated cytotoxicity. Conclusions/Significance: Our findings uncover novel functional properties of PIs within the DC-NK cell cross-talk, unveiling the heterogeneous ability of members of this class drugs to drive the generation of atypical monocyte-derived DCs (MDDCs) showing an aberrant phenotype, a failure to respond appropriately to bacterial endotoxin, a weak ability to prime autologous NK cells, and a high susceptibility to NK cell killing. These unexpected properties might contribute to limit inflammation and viral spreading in HIV-1 infected patients under PIs treatment, and open novel therapeutical perspectives for this class drugs as immunomodulators in autoimmunity and cancer.

AB - Background: HIV-1 Protease Inhibitors, namely PIs, originally designed to inhibit HIV-1 aspartic protease, can modulate the immune response by mechanisms largely unknown, and independent from their activity on viral replication. Here, we analyzed the ability of PIs to interfere with differentiation program of monocytes toward dendritic cell (DCs) lineage, a key process in the inflammatory response. Methodology/Principal Findings: Monocytes from healthy donors were isolated and induced to differentiate in vitro in the presence or absence of saquinavir, ritonavir, nelfinavir, indinavir or amprenavir (sqv, rtv, nlfv, idv, apv, respectively). These drugs demonstrated a differential ability to sustain the generation of immature DCs (iDCs) with an altered phenotype, including low levels of CD1a, CD86, CD36 and CD209. DCs generated in the presence of rtv also failed to acquire the typical phenotype of mature DCs (mDCs), and secreted lower amounts of IL-12 and IL-15. Accordingly, these aberrant mDCs failed to support activation of autologous Natural Killer (NK) cells, and resulted highly susceptible to NK cell-mediated cytotoxicity. Conclusions/Significance: Our findings uncover novel functional properties of PIs within the DC-NK cell cross-talk, unveiling the heterogeneous ability of members of this class drugs to drive the generation of atypical monocyte-derived DCs (MDDCs) showing an aberrant phenotype, a failure to respond appropriately to bacterial endotoxin, a weak ability to prime autologous NK cells, and a high susceptibility to NK cell killing. These unexpected properties might contribute to limit inflammation and viral spreading in HIV-1 infected patients under PIs treatment, and open novel therapeutical perspectives for this class drugs as immunomodulators in autoimmunity and cancer.

UR - http://www.scopus.com/inward/record.url?scp=77955238366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955238366&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0011052

DO - 10.1371/journal.pone.0011052

M3 - Article

VL - 5

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 6

M1 - e11052

ER -